N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide | 449756-36-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide
• 英文别名: N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide；N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide；N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-benzoxazol-5-yl]oxy]propyl]piperazin-1-yl]acetamide
• CAS: 449756-36-9
• 化学式: C₃₁H₃₃F₃N₄O₄
• 分子量: 582.623
• InChiKey: BUSOHISTSQHOLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  91.1
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  5-(oxine-2-ylmethoxy)isoquinoline 、 N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide 生成 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide
  参考文献：
  名称：

  Heteroaryl alkyl piperazine derivatives

  摘要：

  通用公式：1的新化合物及其药学上可接受的酸盐，其中这些化合物在治疗中用于保护骨骼肌免受外伤引起的损伤或在骨骼肌或系统性疾病（如间歇性跛行）后保护骨骼肌，用于治疗休克状态，保护供体组织和器官用于移植，治疗糖尿病，治疗心血管疾病，包括心房和心室心律失常，普林兹梅塔（变异）心绞痛，稳定型心绞痛和运动诱发性心绞痛，充血性心脏病和心肌梗死。

  公开号：

  US20030216409A1
• 作为产物：
  描述：

  2-[(3-Trifluoromethyl)phenyl]benzoxazol-5-ol 在 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide
  参考文献：
  名称：

  Novel inhibitors of fatty acid oxidation as potential metabolic modulators

  摘要：

  We describe the synthesis of novel inhibitors of fatty acid oxidation as potential metabolic modulators for the treatment of stable angina. Replacement of the 2H-benzo[d]1,3-dioxolene ring system in our initial lead 3 with different benzthiazoles, benzoxazoles and introducing small alkyl substituents into the piperazine ring resulted in analogues with enhanced inhibitory activity against 1-(14)[C]-palmitoyl-CoA oxidation in isolated rat heart mitochondria (6, IC50 = 70 nM; 25, IC50 = 23 nM). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.065

文献信息

• Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
  申请人：——

  公开号：US20040029889A1

  公开（公告）日：2004-02-12

  Novel compounds of the general formula (I): and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction. 1

  一般式（I）的新化合物及其药物可接受的酸盐，其中这些化合物在治疗中对保护骨骼肌免受创伤引起的损伤或在肌肉或全身疾病（如间歇性跛行）后保护骨骼肌，治疗休克病状，保存用于移植的供体组织和器官，在治疗心血管疾病包括心房和心室心律失常，普林兹梅塔尔（变异）心绞痛，稳定型心绞痛和运动性心绞痛，充血性心力衰竭和心肌梗死方面有用。
• HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1339701A1

  公开（公告）日：2003-09-03
• US6573264B1
  申请人：——

  公开号：US6573264B1

  公开（公告）日：2003-06-03
• US6849632B2
  申请人：——

  公开号：US6849632B2

  公开（公告）日：2005-02-01
• [EN] HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS<br/>[FR] DERIVES D'HETEROARYLE ALKYLE PIPERAZINE SERVANT D'INHIBITEURS DE L'OXYDATION DES ACIDES GRAS
  申请人：CV THERAPEUTICS INC

  公开号：WO2002064576A1

  公开（公告）日：2002-08-22

  Novel compounds of the general formula (I): and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.